Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2023 07:30 ET | Source: BioAtla, Inc.

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion...
September 06, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 03, 2023 16:01 ET | Source: BioAtla, Inc.

BioAtla to Participate in Upcoming Investor Conferences in August

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 01, 2023 16:01 ET | Source: BioAtla, Inc.

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug...
July 25, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
June 26, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 31, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the Jefferies Healthcare Conference

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 11, 2023 16:01 ET | Source: BioAtla, Inc.

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in...
May 08, 2023 16:05 ET | Source: BioAtla, Inc.

BioAtla to Participate in the JMP Securities Life Sciences Conference

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 04, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...